Akero Therapeutics’ Post

Hepatic stellate cells (HSCs) are a type of 'minority' cell in the liver, but serve critical functions in a healthy liver and in response to injury. When there's an injury to the Liver, these HSCs activate to produce 'scar tissue' in liver fibrosis. Our publication below explains the co-culture we created to 'mimic' the effects liver scarring and develop better therapeutics for this disease. https://lnkd.in/gZjr-R_x

Cereno Scientific is a biotech company developing treatments for the number one killer in the world – cardiovascular disease. The company has been granted the approval from EMA to initiate a first-in-human phase I trial with candidate CS014 – a novel epigenetic HDAC inhibitor. Cereno’s CEO Sten R. Sörensen stopped by the BioStock Studio to share more details about the news. Watch the interview with Cereno‘s CEO Sten R Sörensen below! #BioStockSwe #lifescience #CardiovascularHealth

Discovery Life Sciences has a robust #biorepository of #biospecimens available from #autoimmunedisease patients available for immediate shipment to your facility. PBMCs, plasma, serum and FFPE are all available. Send me a DM if you need an inventory report! #PBMCs #FFPE #tissues #rheumatoidarthritis #SLE #lupus #psoriasis #autoimmune #researchanddevelopment #clinicalsamples

June is #AlzheimersandBrainAwarenessMonth, an important time to raise awareness of the significance of #brainhealth.  At Delix Therapeutics, we're developing first-in-class #neuroplastogens that promote the brain's innate ability to repair itself, and in doing so, pioneering a new era in #CNS disease treatment. Learn more about our science here: https://lnkd.in/eCRnJMv5.

Join us tomorrow at 11:00 am EST! In this presentation, the speaker will review the existing literature related to the potential mechanisms for increased drug hepatotoxicity in patients with chronic liver diseases such as MASLD and cirrhosis. Learn more: https://lnkd.in/eaecXuEP

Join Us in Raising Awareness for Autoimmune Awareness Month! 🎉 💜 🎉 As March unfolds, Avrok Biosciences proudly joins the global community in observing Autoimmune Awareness Month. Our team is not just observers or individuals personally affected by autoimmune diseases, but a group that strives to be active participants on the journey of understanding, treating, and ultimately, curing these complex conditions. Dive into our latest blog post to learn more about the significance of AutoImmune Awareness Month and how you can contribute to supporting autoimmune patients everywhere ➡️ https://lnkd.in/e67Uy_cp #AutoimmuneAwarenessMonth #SupportPatients #CRO #biobanking #patientcentricity #translationalresearch #clinicalresearch

October is Liver Awareness Month! Let’s shine a light on crucial liver conditions like Metabolic dysfunction–associated fatty liver disease (MAFLD) and Metabolic dysfunction-associated steatohepatitis (MASH). 🧐Did you know that #MAFLD affects about 25% of adults in the U.S.? Of these, roughly 20% progress to #MASH, a severe form marked by #liver inflammation and damage that can lead to #cirrhosis or liver cancer. 💡Understanding the disease and managing risk factors like #obesity, #type2diabetes, and metabolic syndrome is crucial. Stay informed and proactive about liver health! ✨Learn more about Inventiva and our initiatives to advance drug development for MASH: https://lnkd.in/eVPfbZs6 #Octoberis4Livers #LiverAwarenessMonth #LiverCancerAwarenessMonth

New data support CAR-T therapy in neuroinflammatory diseases Kyverna Therapeutics has revealed continued positive results for its CAR-T therapy KYV-101 in B cell-driven autoimmune diseases. https://lnkd.in/eBsxGUQN #CellTherapy #DrugDiscovery #NeuroinflammatoryDiseases

🧬✨ Unlocking New Strategies in MASH Treatment: SGLT2 Inhibitors to the Rescue 🛡️🧪 Liver injury and inflammation from metabolic dysfunction-associated steatohepatitis (MASH) are no small foes, especially when auto-aggressive CD8+ T cells enter the fray. But here’s where SGLT2 inhibitors (like Empagliflozin) show their game-changing potential. 🦠🚫 🟢 Key Insights: Protecting the Liver: SGLT2 inhibitors alleviate liver injury, inflammation, and fibrosis in MASH by reining in those rogue CD8+ T cells. Ketogenesis Power-Up: EMPA enhances ketogenesis in CD8+ T cells, with β-hydroxybutyric acid playing a critical role in dampening T cell activation. A Critical Player: Bdh1, a key enzyme in ketogenesis, turns out to be pivotal; when it’s down, MASH symptoms worsen, highlighting its importance in SGLT2i's therapeutic action. Human Impact: Case-control studies echo the animal findings, showing that SGLT2 inhibitors improve liver health in MASH patients by targeting the immune response. 🧩 Why This Matters: MASH has always been a complex battlefield, but the discovery that SGLT2 inhibitors can directly modulate CD8+ T cell activity offers a novel and promising therapeutic approach. By tweaking immune cell metabolism, we’re not just treating the symptoms but tackling one of the root causes of liver damage. This opens up exciting new avenues for managing MASH, with potential benefits extending far beyond what we thought possible. 🌐🩺 link: https://lnkd.in/gAGZj_MY #LiverHealth #MASH #Immunometabolism #SGLT2Inhibitors #InnovationInTherapy

....“The competitive landscape has evolved very rapidly, with multiple companies rolling out programs across immunology indications, often leading with SLE as a first indication. Hence, the field is very crowded.”.... ...Galapagos has decided to focus on its CAR-T programs in oncology where it believes it can “make the biggest impact on patients” with its decentralized manufacturing capabilities and 7-day vein-to-vein approach, the spokesperson added... #competitvelandscape #autoimmunedisease #autoimmune #carttherapies #cartcell #pointofcare #decentralizedmanufacturing #celltherapy #cellandgenetherapy #regenerativemedicine #advancedtherapies #oncology #cancer #lupus #CD19 #biotech #biotechnology #lifesciences #healthcare #pipeline #prioritization #pharmaceutical #pharma Paul Stoffels, MD #manufacturing #manufacturingcapabilities #patientcare #patientaccess #competition